

FORM 3

**UNITED STATES SECURITIES AND EXCHANGE
COMMISSION
Washington, D.C. 20549**

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response...	0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person * Northey Robert Allen <small>(Last) (First) (Middle)</small> C/O OCULUS INNOVATIVE SCIENCES, INC., 1129 N. MCDOWELL BLVD. <small>(Street)</small> PETALUMA, CA 94954 <small>(City) (State) (Zip)</small>	2. Date of Event Requiring Statement (Month/Day/Year) 09/01/2015	3. Issuer Name and Ticker or Trading Symbol Oculus Innovative Sciences, Inc. [OCLS]	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input type="checkbox"/> Director <input type="checkbox"/> 10% Owner <input checked="" type="checkbox"/> Officer (give title below) <input type="checkbox"/> Other (specify below) Exec. VP of Res & Devlpment	5. If Amendment, Date Original Filed(Month/Day/Year)
		6. Individual or Joint/Group Filing(Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person	

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)


1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Stock Option (Right to Buy)	10/01/2005	10/01/2015	Common Stock	1,964	\$ 71.12	D	
Stock Option (Right to Buy)	07/05/2005	01/03/2016	Common Stock	714	\$ 71.12	D	
Stock Option (Right to Buy)	06/15/2007	06/15/2017	Common Stock	230	\$ 50.89	D	
Stock Option (Right to Buy)	06/15/2007	06/15/2017	Common Stock	4,591	\$ 50.89	D	
Stock Option (Right to Buy)	12/09/2008	12/09/2018	Common Stock	14,286	\$ 2.8	D	
Stock Option (Right to Buy)	02/25/2010	02/25/2020	Common Stock	12,857	\$ 12.81	D	
Stock Option (Right to Buy)	05/17/2011	05/17/2021	Common Stock	15,714	\$ 13.23	D	
Stock Option (Right to Buy)			Common				

Buy)	(1)	09/19/2023	Stock	18,729	\$ 2.97	D	
Stock Option (Right to Buy)	(2)	03/04/2024	Common Stock	100,702	\$ 3.9	D	
Stock Option (Right to Buy)	(3)	08/21/2025	Common Stock	50,000	\$ 1.16	D	

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Northey Robert Allen C/O OCULUS INNOVATIVE SCIENCES, INC. 1129 N. MCDOWELL BLVD. PETALUMA, CA 94954			Exec. VP of Res & Devlpment	

Signatures

/s/ Robert Miller as attorney-in-fact		09/02/2015
		Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Options will vest 1/36th per month over a three-year vesting schedule commencing on September 19, 2013.

(2) Options will vest 1/36th per month over a three-year vesting schedule commencing on March 4, 2014.

Options will only vest in whole or in part in the event the executive achieves a minimum of 80% of each of his Target Milestones in the fiscal year ending March 31, 2016 as determined by the Compensation Committee by June 30, 2016. If such executive does not achieve

(3) 80% of each of their Target Milestones, then 100% of the options will expire. If the executive achieves at least 80% of their Target Milestones by March 31, 2016, then 80% of the executive's options will vest on June 30, 2016. The vesting of the remaining 20% is in the discretion of the Compensation Committee and will vest on June 30, 2016, if at all.

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

**OCULUS INNOVATIVE SCIENCES, INC.
LIMITED POWER OF ATTORNEY FOR SECTION 13 AND SECTION 16 FILINGS**

I, Robert Northey, do hereby make, constitute and appoint Robert E. Miller and Jim Schutz, each of them acting individually, as my true and lawful attorneys for the purpose hereinafter set forth, effective as of this 27th day of August 2015.

References in this limited power of attorney to "my Attorney" are to each of the persons named above and to the person or persons substituted hereunder pursuant to the power of substitution granted herein.

I hereby grant to my Attorney, for me and in my name, place and stead, the power:

1. To execute for and on my behalf, in my capacity as a stockholder of Oculus Innovative Sciences, Inc., a Delaware corporation (the "Company"), Schedule 13D and Schedule 13G, and all and any amendments thereto, in accordance with Section 13 of the Securities Exchange Act of 1934 and the rules and regulations promulgated thereunder (the "Exchange Act");
2. To execute for and on my behalf in my capacity as a director or stockholder of the Company, Form 3, Form 4, and Form 5, and all and any amendments thereto, in accordance with Section 16(a) of the Exchange Act;
3. To do and perform any and all acts for and on my behalf that may be necessary or desirable to complete and execute any such Schedule 13D, Schedule 13G, Form 3, Form 4, and Form 5 or any amendment thereto, and to timely file such schedule, form or amendment thereto with the United States Securities and Exchange Commission (the "SEC") and any stock exchange or similar authority; and
4. To take any other action of any type whatsoever that, in the opinion of my Attorney, may be necessary or desirable in connection with the foregoing grant of authority, it being understood that the documents executed by my Attorney pursuant to this limited power of attorney shall be in such form and shall contain such terms and conditions as my Attorney may approve.

I hereby grant to my Attorney full power and authority to do and to perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted as fully to all intents and purposes as I might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that my Attorney shall lawfully do or cause to be done by virtue of this limited power of attorney and the rights and powers herein granted. I acknowledge and agree that neither my Attorney nor the Company is assuming any of my responsibilities to comply with the Exchange Act.

This limited power of attorney shall remain in full force and effect until I am no longer required to file any Schedule 13D, Schedule 13G, Form 3, Form 4 or Form 5 with respect to my holdings of, and transactions in, securities of the Company, unless earlier revoked by me in a signed writing delivered to my Attorney and any substitutes therefor, if any. This limited power of attorney may be filed with the SEC as a confirming statement of the authority granted herein.

IN WITNESS WHEREOF, I have hereunto set my hand to this instrument on the date first above written.

/s/ Robert Northey
Robert Northey